Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab.
Panciroli C, Lucente G, Vidal L, Carcereny E, Quiroga V, Pardo JC, Romeo M, Estival A, Manzano JL, Pardo B, Velarde JM, Esteve AM, Lopez D, Mañes A, Tuset V, Villà S, Quintero CB. Panciroli C, et al. Among authors: esteve am. Clin Transl Oncol. 2020 Mar;22(3):411-419. doi: 10.1007/s12094-019-02143-6. Epub 2019 May 29. Clin Transl Oncol. 2020. PMID: 31144211
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
Balana C, Vaz MA, Manuel Sepúlveda J, Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las Peñas R, Fuster J, Gironés R, Navarro LM, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-García M, Berrocal A, Gallego O, Luque R, Perez-Martín FJ, Esteve A, Munne N, Domenech M, Villa S, Sanz C, Carrato C. Balana C, et al. Neuro Oncol. 2020 Dec 18;22(12):1851-1861. doi: 10.1093/neuonc/noaa107. Neuro Oncol. 2020. PMID: 32328662 Free PMC article. Clinical Trial.
RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma.
Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí O, Martinez-García M, Mallo M, Gut M, Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T, Oleaga L, Gil-Gil M, de Quintana-Schmidt C, Valduvieco I, Martinez-Cardús A, Bellosillo B, Muñoz-Marmol AM, Esteve A, Domenech M, Camins A, Craven-Bartle J, Villa S, Marruecos J, Domenech S, de la Iglesia N, Balana C. Esteve-Codina A, et al. Among authors: esteve a. Clin Cancer Res. 2021 Jan 15;27(2):645-655. doi: 10.1158/1078-0432.CCR-20-2141. Epub 2020 Oct 26. Clin Cancer Res. 2021. PMID: 33106291
Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
Stefanovic M, Calvet G, Pérez-Montero H, Esteve A, Bujalance MV, Navarro-Martín A, Fernández MDA, González FF, Borras SM, Borbalas AL, Fernandez MN, Garau MM, Calduch AL, Edo FG. Stefanovic M, et al. Clin Transl Oncol. 2023 Jan;25(1):199-206. doi: 10.1007/s12094-022-02923-7. Epub 2022 Sep 6. Clin Transl Oncol. 2023. PMID: 36068449
Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.
Romeo M, Gil-Martín M, Gaba L, Teruel I, Taus Á, Fina C, Masvidal M, Murata P, Fernández-Plana J, Martínez A, Pérez C, García Y, Rodriguez V, Cros S, Parera M, Zanui M, Catot S, Pardo B, Plaja A, Esteve A, Barretina-Ginesta MP. Romeo M, et al. Cancers (Basel). 2022 Sep 11;14(18):4414. doi: 10.3390/cancers14184414. Cancers (Basel). 2022. PMID: 36139574 Free PMC article.
Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.
Plaja A, Teruel I, Ochoa-de-Olza M, Cucurull M, Arroyo ÁJ, Pardo B, Ortiz I, Gil-Martin M, Piulats JM, Pla H, Fina C, Carbó A, Barretina-Ginesta MP, Martínez-Román S, Carballas E, González A, Esteve A, Romeo M. Plaja A, et al. Int J Mol Sci. 2023 Jul 13;24(14):11420. doi: 10.3390/ijms241411420. Int J Mol Sci. 2023. PMID: 37511180 Free PMC article.
Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Font A, Domenech M, Buisan O, Lopez H, González A, Etxaniz O, Matas M, Elias X, Gomez M, Figols M, Horneros J, Pardo JC, Notario L, Ruiz de Porras V, Perez I, Areal J, Esteve A. Font A, et al. World J Urol. 2022 Nov;40(11):2627-2634. doi: 10.1007/s00345-022-04147-4. Epub 2022 Sep 15. World J Urol. 2022. PMID: 36107212
41 results